Please assess the completion status of the following clinical trial:

Trial Title: A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males , between 18 and 55 years of age, inclusive.~* Body mass index (BMI) within the range of 20 to 30 kg/m2, inclusive.~* In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs.~* Adequate hepatic, renal, heart, and hematologic functions~* Male subjects who are either sterile or agree to use and get the agreement of their sexual partners to use , during the period from informed consent until 90 days following Study Completion, 1 of the following approved methods of contraception: condom, use by female sexual partner of an intrauterine device, contraceptive sponge, diaphragm, or use of a cervical cap; or an oral, implantable, transdermal, injectable contraceptives or other contraceptive measures.~* Able to comprehend and willing to sign an informed consent form (ICF).~Exclusion Criteria:~* disease history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric disorder(as determined by the Investigator).~* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.~* serum total bilirubin\>34.2 umol/L；~* serum albumin\<35 g/L；~* GFR \< 80 mL/min/1.73m2. Algorithm: GFR (mL/min/1.73m2) =186 × (SCr)-1.154 × (Age)-0.203, Scr= serum creatinine, mg/dL；~* Blood pressure greater than 140/90.~* History or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant.~* Smoking more than 10 cigarettes daily without intention to quit smoking during study.~* History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection that would potentially alter absorption and/or excretion of orally administered drugs as determined by the investigator (appendectomy and/or hernia repair may be allowed).~* Significant allergy history(eg. drug allergy); acute allergic rhinitis or food allergy within 2 weeks prior to informed consent.~* Donation of blood or plasma ≥ 500 mL from 30 days prior to informed consent, or of blood or plasma ≥250 mL from 2 weeks prior to informed consent.~* Receipt of blood products within 2 months prior to informed consent;~* Poor peripheral venous access.~* Participants who are positive for hepatitis B surface antigen (HBs antigen) or hepatitis B core antibody , hepatitis C virus (HCV) antibody;~* Participants who are human immunodeficiency virus (HIV)-positive;~* Diagnosis of alcoholism or drug addiction within 1 year prior to informed consent.~* Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 5 half-lives or 28 days, whichever is longer prior to informed consent.~* Use of any prescription medications or products within 14 days prior to informed consent.~* Use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic, herbal,) within 7 days prior to informed consent.~* Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices, or beverages within 72 hours prior to informed consent.~* Use of known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant derived preparations such as St. John's Wort, etc.) for a period of 60 days prior to first dose;~* principal investigator, investigator, pharmacist, Clinical Research Coordinator or any personnel related to this study.~* Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sulfatinib ,after general diet (Type: EXPERIMENTAL): First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
- Sulfatinib, before general diet (Type: EXPERIMENTAL): First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete